Date: 2015-04-14
Type of information: Collaboration agreement
Compound: coagulation testing solutions including CP3000 coagulation instrument
Company: Abbott (USA - IL) Sekisui Diagnostics (Japan)
Therapeutic area: Diagnostic - Hematological diseases - Genetic diseases - Cardiovascular diseases
Type agreement: collaboration
Action mechanism: The Sekisui CP3000 system features high-quality reagents, small sample volume requirements and offers a combination of high-throughput and a compact footprint. With a broad assay menu and rapid result turnaround time, the CP3000 can rapidly meet the workflow needs of laboratories of all sizes, while providing high quality and reliable results. The system will aim to seamlessly connect to Abbott\'s ACCELERATOR a3600 lab automation platform and middleware solutions.
Disease:
Details: * On April 14, 2015, Abbott and Sekisui announce an agreement to offer coagulation testing solutions for laboratories worldwide. Coagulation tests measure a person\'s blood clotting ability, which can help doctors assess risks of excessive bleeding or developing clots. Under the agreement, Abbott will be the exclusive distributor of Sekisui\'s new CP3000 coagulation instrument in the United States , Europe and other regions that recognize CE Mark. Sales of the CP3000 are expected to begin later this year in Europe , countries that recognize CE Mark and non-regulated countries, and in the United States in 2016. Abbott will have non-exclusive distribution rights with Sekisui in China , Hong Kong , Japan and Macau .
Financial terms:
Latest news:
